BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Treatment
156 results:

  • 1. [Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
    Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
    Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
    Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
    J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Association of a novel frameshift variant and a known deleterious variant in MMR genes with Lynch syndrome in Chinese families.
    Li J; Ni H; Wang X; Cheng W; Li L; Cheng Y; Liu C; Li Y; Deng A
    World J Surg Oncol; 2024 Jan; 22(1):36. PubMed ID: 38280988
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [A Case of Transverse Colon cancer Associated with Lynch Syndrome with Excellent Response to Pembrolizumab].
    Mori Y; Chika N; Suzuki O; Matsuyama T; Ito T; Muta Y; Chiyonobu N; Hatano S; Momose S; Tanabe N; Akagi K; Ishida H
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1111-1113. PubMed ID: 38035847
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Metastasis of endometrial adenocarcinoma masquerading as a primary rectal cancer: A rare case report with literature review.
    Li M; Zheng W
    Medicine (Baltimore); 2023 Nov; 102(46):e36170. PubMed ID: 37986305
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Linked-color imaging versus high definition white-light endoscopy for evaluation of post-polypectomy scars of nonpedunculated lesions: LCI-Scar study.
    Ortiz O; Daca-Alvarez M; Rivero-Sánchez L; Saez De Gordoa K; Moreira R; Cuatrecasas M; Balaguer F; Pellisé M
    Endoscopy; 2024 Apr; 56(4):283-290. PubMed ID: 37931908
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
    Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
    Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Phase II Trial of Nivolumab in Metastatic Rare cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
    Okuma HS; Watanabe K; Tsuchihashi K; Machida R; Sadachi R; Hirakawa A; Ariyama H; Kanai M; Kamikura M; Anjo K; Hiramitsu A; Sekine S; Okita N; Mano H; Nishikawa H; Nakamura K; Yonemori K
    Clin Cancer Res; 2023 Dec; 29(24):5079-5086. PubMed ID: 37819940
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of msh6 in colorectal cancer stem cells.
    Paul S; Chatterjee S; Sinha S; Dash SR; Pradhan R; Das B; Goutam K; Kundu CN
    Expert Opin Ther Targets; 2023; 27(10):999-1015. PubMed ID: 37787493
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Glioma arising in the setting of mismatch repair deficiency-rare or are we missing it?
    Goyal A; Rao S; Rishi KS; Ramaswamy V; Sadashiva N; Santosh V
    Childs Nerv Syst; 2024 Jan; 40(1):233-237. PubMed ID: 37733272
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Constitutional Mismatch Repair Deficiency Syndrome as a Cause of Numerous Malignancies in a Teenage Patient-A Case Report.
    Samborska M; Galli D; Achkar R; Thambyrajah S; Derwich K
    J Pediatr Hematol Oncol; 2023 Oct; 45(7):e917-e920. PubMed ID: 37526375
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome.
    Bolivar AM; Duzagac F; Sinha KM; Vilar E
    Mol Aspects Med; 2023 Oct; 93():101204. PubMed ID: 37478804
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
    Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
    Mutat Res; 2023; 827():111831. PubMed ID: 37453313
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.
    Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
    Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Survival in relation to time to start of curative treatment of colon cancer: A national register-based observational noninferiority study.
    Rydbeck D; Bock D; Haglind E; Angenete E; Onerup A
    Colorectal Dis; 2023 Aug; 25(8):1613-1621. PubMed ID: 37317006
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
    Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
    JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Microsatellite instability in non-endometrioid ovarian epithelial tumors: a study of 400 cases comparing immunohistochemistry, PCR, and NGS based testing with mutation status of MMR genes.
    Hájková N; Bártů MK; Cibula D; Drozenová J; Fabian P; Fadare O; Frühauf F; Hausnerová J; Hojný J; Krkavcová E; Laco J; Lax SF; Matěj R; Méhes G; Michálková R; Němejcová K; Singh N; Stolnicu S; Švajdler M; Zima T; McCluggage WG; Stružinská I; Dundr P
    Transl Res; 2023 Oct; 260():61-68. PubMed ID: 37244485
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Germline drivers of gynecologic carcinosarcomas.
    Sia TY; Gordhandas SB; Birsoy O; Kemel Y; Maio A; Salo-Mullen E; Sheehan M; Hensley ML; Rubinstein M; Makker V; Grisham RN; O'Cearbhaill RE; Roche KL; Mueller JJ; Leitao MM; Sonoda Y; Chi DS; Abu-Rustum NR; Berger MF; Ellenson LH; Latham A; Stadler Z; Offit K; Aghajanian C; Weigelt B; Mandelker D; Liu YL
    Gynecol Oncol; 2023 Jul; 174():34-41. PubMed ID: 37149903
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
    Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
    Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
    Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
    Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 8.